Advances in the treatment of gastric cancer: 2020–2021

Purpose of review To review studies from 2020 to 2021 in esophagogastric cancer. Recent findings After up front D2 gastrectomy for lymph node-positive gastric cancer, 6 months of adjuvant chemotherapy with S-1 and oxaliplatin achieved superior disease-free survival (DFS) compared with 1 year of S-1. The addition of adjuvant radiotherapy, however, added no benefit. After chemoradiotherapy and surgery in esophageal and gastroesophageal junction cancer, in patients with residual disease found at surgery, 1 year of adjuvant nivolumab substantially improved DFS compared with observation alone, leading to regulatory approval for adjuvant nivolumab. In metastatic esophagogastric cancer, the addition of either pembrolizumab or nivolumab to first-line chemotherapy improved response, disease free, and overall survival with the greatest survival benefit dependent on programmed death receptor ligand, programmed death receptor ligand -1 status, leading to regulatory approval for these agents. A preliminary report of a phase 3 trial adding pembrolizumab to first-line chemotherapy with trastuzumab in HER2-positive gastric cancer reported a significant improvement in response, leading to regulatory approval for pembrolizumab. The fibroblast growth factor receptor appears to be a promising new target in gastroesophageal cancer based on phase 2 data for bemarituzumab. Summary Optimal adjuvant chemotherapy after D2 resection of node-positive gastric cancer is 6 months of a flu...
Source: Current Opinion in Gastroenterology - Category: Gastroenterology Tags: STOMACH AND DUODENUM: Edited by Tilak U. Shah Source Type: research

Related Links:

Expert Opin Emerg Drugs. 2021 Nov 23. doi: 10.1080/14728214.2021.2010705. Online ahead of print.ABSTRACTINTRODUCTION: Gastric cancer (GC) and gastro-oesophageal junction cancer (GOJC) patients have a poor prognosis with a 5-year relative survival rate of 6% in the metastatic setting. Despite the well-characterized molecular features, patients have been historically considered for treatment with universal and undistinguishing chemotherapies and targeted agents, except for the HER2-positive population and some immunological approaches.AREAS COVERED: In this review we discuss the intrinsic characteristic of GC/GOJC from an ep...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Authors: Source Type: research
Gastric cancer (GC) remains one of the most common and deadly cancers worldwide, even if its incidence has decreased over time, mainly because of prevention and treatment of Helicobacter pylori infection[1]. Contrarily, the incidence of gastro-esophageal junction (GEJ) adenocarcinomas has increased, attributable to smoking and elevated body mass index (BMI) [2]. Much progress has been made in the management of advanced G/GEJ adenocarcinomas: the identification of molecular sub-groups benefiting from specific therapies (HER2 positive tumors, MSI/dMMR and EBV positive tumors, FGFR amplified tumors, etc)[3 –6], the intr...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research
Cancers, Vol. 13, Pages 4591: Combined Therapy of Locally Advanced Oesophageal and Gastro–Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors Cancers doi: 10.3390/cancers13184591 Authors: Milan Vošmik Jindřich Kopecký Stanislav John Ondřej Kubeček Petr Lochman Aml Mustafa Banni Libor Hruška Igor Sirák The following main treatment approaches are currently used in locally advanced adenocarcinomas of the oesophagus and gastrooesophageal junction (GOJ): preoperative chemoradiotherapy and surgery, and perioperative chemotherapy and s...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Anthracycline and trastuzumab are essential adjuvant therapies for a variety of cancers, particularly breast, and gastric and esophageal cancers.1 Anthracyclines inhibit topoisomerase II which arrests DNA growth, while trastuzumab is a monoclonal antibody directed against the extracellular portion of HER2 receptor.2 Whilst prolonging cancer-related survival, these agents can induce drug-related cardiotoxicity. This causes an increased risk of heart failure (HF).3 Cardioprotective agents used to mitigate cardiotoxicity, such as angiotensin antagonists, angiotensin receptor blockers and beta ‐blockers, are often poorly tol...
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Conclusion: To our knowledge, this is the first study that HER2 overexpression correlates with more aggressive colorectal cancer in North African population. Our study shows that HER2 overexpression associates with right colon surgeries. Also, the correlation of mRNA and protein expression could warrant the implementation of a nationwide screening program for HER2 positivity in CRC patients. Taken together, stratifying patients according to HER2 expression can help in the diagnosis and prognosis of CRC patients from North African origin.PMID:34319852 | DOI:10.1080/19932820.2021.1955462
Source: Libyan Journal of Medicine - Category: General Medicine Authors: Source Type: research
This article reviews recent randomised clinical trials on systemic treatment of oesophago-gastric cancers in the perioperative and metastatic setting. Recent findings Adding nivolumab to first-line chemotherapy improved survival in patients with metastatic gastric/gastro-oesophageal junction/oesophageal adenocarcinoma with PD-L1 combined positive score (CPS) ≥ five in a global trial and progression-free survival in metastatic gastric/gastro-oesophageal junction cancers in an Asian trial. The addition of pembrolizumab to first-line chemotherapy improved survival in metastatic oesophageal cancer patients, with the ...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz and Francesco Sclafani Source Type: research
Over one million cancer related deaths are attributable to esophageal and gastric cancer worldwide annually, ranking third and sixth as most frequent causes of global cancer mortality. [1] Neoadjuvant chemoradiotherapy (nCRT) is commonly used for the treatment of patients with esophageal adenocarcinoma (EAC), while perioperative chemotherapy is often administered to patients with gastric cancer. [1,2] Notwithstanding the benefit gained with multimodality treatment in both cancer types, the prognosis remains dismal with a high distant relapse rate following surgery.[1] Optimization of treatment is thus urgently needed.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research
This article summar izes the milestones in the development of margetuximab leading to this first approval.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
röm Ann M. Hopkins High expression of Junctional Adhesion Molecule-A (JAM-A) has been linked with poor prognosis in several cancers, including breast cancers overexpressing the human epidermal growth factor receptor-2 (HER2). Furthermore, JAM-A expression has been linked with regulating that of HER2, and associated with the development of resistance to HER2-targeted therapies in breast cancer patients. The purpose of this study was to establish a potential relationship between JAM-A and HER2 in HER2-overexpressing gastro-esophageal (GE) cancers. Interrogation of gene expression datasets revealed that high JAM-A ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionOur study supports the hypothesis that EAC exhibits clinicopathological characteristics, prognostic factors, and treatment outcomes comparable to intestinal GEJ-AC and GAC.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Esophagus Cancer | Gastrectomy | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Study